CMET-30. LEPTOMENINGEAL METASTASES: OUTCOMES WITH AGGRESSIVE MULTIMODALITY TREATMENT

INTRODUCTION: Leptomeningeal metastases (LM) affect 5–8% of cancer patients; median survivals historically have ranged from 12–16 weeks. Earlier intervention, multimodal treatment, intrathecal chemotherapy, and targeting relevant molecular drivers may improve outcomes. METHODS: Under an IRB-approved...

詳細記述

保存先:
書誌詳細
出版年:Neuro Oncol
主要な著者: Smith, Rachel, Boman, Christina, Thatikonda, Srivani, Dziuk, Timothy, Tumu, Hari, Hellerstedt, Beth, Patt, Debra, Nuesch, Carl, Pearson, Rachel, Cohen, Karen, Kemper, Craig, Sheinbein, Courtney, Kim, Stanley, Fain, Jerry, de Celis, Carlos Rubin, Melear, Jason, Groves, Morris D
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2017
主題:
Abstracts
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692985/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.177
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料